TAVR for Asymptomatic Aortic Stenosis: Standard of Care or Still Controversial?
Key Summary
- Early aortic valve replacement (including TAVR) shows favorable outcomes in select asymptomatic severe AS populations, but evidence remains limited.
- Current guidelines recommend intervention primarily in asymptomatic patients with LVEF <50% or other high-risk features, though routine early treatment is not yet standard.
- Risk stratification using biomarkers, imaging, and hemodynamic progression is critical, as true asymptomatic status is often uncertain and symptom reporting is delayed.
Saint Mary's Regional Medical Center
At the 2026 Cardiovascular Research Technologies (CRT) conference, Sabeeda Kadavath, MD, discussed the role of transcatheter aortic valve replacement (TAVR) in asymptomatic severe aortic stenosis (AS). The key takeaway: while early intervention is promising, it remains controversial due to limited evidence and challenges in identifying truly asymptomatic patients. The session highlighted current guideline recommendations, gaps in risk stratification, and emerging randomized trial data.
Epidemiology and Clinical Dilemma
Severe AS is predominantly degenerative in the United States, affecting approximately 3.4% of US adults older than 75 years, and 12% of this demographic globally. Notably, one-third to one-half of patients are asymptomatic, which carries an estimated ~1% annual risk of sudden death—higher than the general population.
This creates a central clinical dilemma: whether to pursue early AVR or continue “watchful waiting,” given periprocedural mortality risks (≈1% to 3% in younger patients, rising to 4% to 8% in older populations).
Limitations of Symptom-Based Management
Traditional paradigms rely on symptom onset, which is associated with sharply reduced survival (eg, 3-5 years with angina/syncope, 1-2 years with heart failure). However, symptom recognition is often delayed, with studies suggesting up to a 90-day lag in reporting, even in structured valve clinics. During surgical wait times, mortality risk may increase substantially.
Risk Stratification and Guideline Recommendations
Current ACC/AHA and ESC guidelines support AVR in asymptomatic severe AS primarily when left ventricular ejection fraction (LVEF) is less than 50% or when patients are undergoing concomitant cardiac surgery (Class Ib). As highlighted in the ESC 2021 guidance, intervention may also be considered in patients with abnormal exercise testing, including symptom provocation or a drop in blood pressure of greater than 20 mm Hg.
Beyond these criteria, risk stratification is increasingly incorporating markers of disease severity and progression. These include markedly elevated BNP levels, very high transvalvular gradients, and rapid hemodynamic progression. Structural and functional markers—including LV damage, left atrial volume, pulmonary vasculature, and right-sided changes—have been proposed as potential surrogate markers to guide timing of intervention.
Of importance, Dr Kadavath noted that not all patients are able to undergo exercise testing, which limits the criteria that can be used for assessment.
Knowledge Gaps in Asymptomatic Severe AS
Dr. Kadavath emphasized several unresolved questions that limit routine adoption of early TAVR, including:
- True symptom status: Many “asymptomatic” patients may have unrecognized or underreported symptoms, complicating clinical decision-making.
- Optimal biomarkers: While BNP is useful, it remains unclear whether it is sufficient alone or if additional biomarkers are needed.
- Disease classification: Current grading based on valve area and gradients may be insufficient; expanded classification systems may be needed, similar to other valvular diseases.
Patient selection for early intervention: Evidence is limited for broader use in lower-risk populations, particularly outside highly selected trial cohorts.
Evidence From Randomized Trials
Four key randomized trials—RECOVERY, AVATAR, EARLY TAVR, and EVOLVED—inform current practice:
- RECOVERY: Early surgery reduced cardiovascular mortality vs watchful waiting, though limited by small sample size, high crossover (74%), lack of stress testing to confirm true asymptomatic status, and the fact that all of the patients underwent surgical AVR.
- AVATAR: Showed similar benefits to RECOVERY but had methodological limitations including single-center predominance, no core lab analyses, and procedure delays for the early surgery cohort due to COVID-19.
- EARLY TAVR: This larger trial (~1000 patients) demonstrated improved primary outcomes with early TAVR compared with the group under clinical surveillance.
- EVOLVED: Evaluated both TAVR and SAVR strategies and found no difference between patients treated early vs conservatively in terms of all-cause death or hospitalization related to AS.
Conclusion
Early TAVR for asymptomatic severe AS is an emerging but not yet definitive strategy. Current evidence supports selective intervention in high-risk patients, while routine early treatment remains under investigation Improved identification of truly asymptomatic patients—through biomarkers, imaging, and functional assessment—will be essential to refine future indications.
Sabeeda Kadavath, MD, FACC, FSCAI, is a structural interventional cardiologist at Saint Mary’s Regional Medical Center in Russellville, Arkansas.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Journal of Invasive Cardiology or HMP Global, their employees, and affiliates.
